Malin Corporation PLC Immunocore appoints Chief Executive Officer (3036M)
January 07 2019 - 1:00AM
UK Regulatory
TIDM0Y71
RNS Number : 3036M
Malin Corporation PLC
07 January 2019
Malin Corporation plc
("Malin")
Immunocore appoints Bahija Jallal as Chief Executive Officer
- Malin owns approximately 10% of Immunocore, a Malin Priority Portfolio Asset -
Dublin-Ireland, 7 January 2019: Malin Corporation plc (ISE:MLC),
a company investing in highly innovative life sciences companies,
is pleased to note that Immunocore has appointed Bahija Jallal as
Chief Executive Officer and Director of the Board.
Bahija Jallal joins from AstraZeneca where she was President and
head of its global biologics research and development unit,
MedImmune. She was a member of the senior executive team at
AstraZeneca reporting to the CEO. During her time at MedImmune, she
oversaw significant growth in the AstraZeneca biologics pipeline
across a range of disease areas.
"Bahija Jallal's appointment as CEO of Immunocore strengthens
the company's management team and signals that it is entering a
period of significant clinical and commercial maturity," said
Jean-Michel Cossery, Non-Executive Director of Malin and Malin's
Immunocore Board designate. "With significant leadership experience
and an impressive scientific pedigree, she is ideally suited to
lead Immunocore at this exciting time as it focuses on the
approaching Biologics License Application submission for its lead
asset, IMCgp100 and progressing its broad pipeline. Immunocore is a
Malin Priority Portfolio Asset and Bahija's appointment will
support this company's momentum towards the creation of value for
patients and investors."
Malin owns approximately 10% of Immunocore and carried its
investment in Immunocore at EUR85.1 million at 30 June 2018 in its
portfolio fair value estimate under International Private Equity
Valuation guidelines.
A copy of Immunocore's press release is available to view here:
https://www.immunocore.com/news-hub/news
ENDS
For further information, please contact:
Malin
Jessica Bergin, Director of Investor Relations & External
Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Jonathan Birt
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com
Powerscourt (Ireland PR)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com
Davy Corporate Finance (ESM Adviser)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
About Malin Corporation plc
Malin (ISE:MLC) is a company investing in highly innovative life
sciences companies. Its purpose is to create shareholder value
through the application of long-term capital and operational and
strategic expertise to a diverse range of global healthcare
businesses. Malin has a focus on innovative businesses underpinned
by exceptional science and works with its investee companies,
providing strategic and financial support to enable them to reach
their value potential. Malin is headquartered and domiciled in
Ireland and listed on Euronext Dublin. For more information visit
www.malinplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGURAGUPBPGQ
(END) Dow Jones Newswires
January 07, 2019 02:00 ET (07:00 GMT)
Malin (LSE:0Y71)
Historical Stock Chart
From Apr 2024 to May 2024
Malin (LSE:0Y71)
Historical Stock Chart
From May 2023 to May 2024